Bristol-Myers Squibb shares rose more than 5% in the premarket and are now at $62.31. The company previously assessed ADMILPARANT's phase III ALOFT-IPF trial to treat idiopathic pulmonary fibrosis in adults reached a major endpoint.

Bristol-Myers Squibb shares rose more than 5% in the premarket and are now at $62.31. The company previously assessed ADMILPARANT's phase III ALOFT-IPF trial to treat idiopathic pulmonary fibrosis in adults reached a major endpoint.